The current earnings forecast score of Odyssey Therapeutics Ord Shs (Proposed) is 8.80, ranking 53 out of 387 in the Biotechnology & Medical Research industry.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
35.000
Target Price
+96.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Odyssey Therapeutics Ord Shs (Proposed)
ODTX
5
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is the analyst rating for Odyssey Therapeutics Ord Shs (Proposed)?
Based on the ratings of Odyssey Therapeutics Ord Shs (Proposed)'s stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.